Equities analysts expect Innophos Holdings, Inc. (NASDAQ:IPHS) to report earnings of $0.83 per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Innophos’ earnings. Innophos reported earnings of $0.78 per share during the same quarter last year, which would suggest a positive year-over-year growth rate of 6.4%. The firm is scheduled to issue its next earnings results on Tuesday, October 30th.

According to Zacks, analysts expect that Innophos will report full year earnings of $2.70 per share for the current year. For the next fiscal year, analysts anticipate that the business will post earnings of $3.00 per share. Zacks Investment Research’s EPS calculations are an average based on a survey of analysts that cover Innophos.

Innophos (NASDAQ:IPHS) last issued its quarterly earnings data on Monday, July 30th. The specialty chemicals company reported $0.55 earnings per share for the quarter, missing analysts’ consensus estimates of $0.65 by ($0.10). The firm had revenue of $206.73 million for the quarter, compared to the consensus estimate of $213.40 million. Innophos had a return on equity of 14.28% and a net margin of 2.21%. The company’s revenue was up 15.4% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.57 EPS.

A number of equities research analysts recently weighed in on IPHS shares. TheStreet upgraded Innophos from a “c+” rating to a “b” rating in a research report on Wednesday, May 30th. BidaskClub upgraded Innophos from a “hold” rating to a “buy” rating in a research report on Wednesday, June 6th. Finally, Zacks Investment Research lowered Innophos from a “buy” rating to a “hold” rating in a research report on Thursday, July 5th.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in IPHS. Itau Unibanco Holding S.A. bought a new stake in shares of Innophos in the 2nd quarter valued at about $144,000. Raymond James & Associates bought a new stake in shares of Innophos in the 2nd quarter valued at about $209,000. Ifrah Financial Services Inc. bought a new stake in shares of Innophos in the 2nd quarter valued at about $210,000. Alps Advisors Inc. bought a new stake in shares of Innophos in the 2nd quarter valued at about $213,000. Finally, Piedmont Investment Advisors LLC bought a new stake in shares of Innophos in the 2nd quarter valued at about $217,000. Hedge funds and other institutional investors own 93.83% of the company’s stock.

IPHS stock traded up $0.16 during midday trading on Friday, reaching $45.74. 243,231 shares of the stock were exchanged, compared to its average volume of 49,169. The firm has a market capitalization of $896.87 million, a P/E ratio of 18.59 and a beta of 0.73. Innophos has a 52 week low of $38.66 and a 52 week high of $51.34. The company has a quick ratio of 1.34, a current ratio of 2.75 and a debt-to-equity ratio of 0.99.

The business also recently declared a quarterly dividend, which was paid on Wednesday, September 5th. Shareholders of record on Friday, August 17th were given a $0.48 dividend. The ex-dividend date was Thursday, August 16th. This represents a $1.92 dividend on an annualized basis and a dividend yield of 4.20%. Innophos’s dividend payout ratio (DPR) is presently 78.05%.

About Innophos

Innophos Holdings, Inc, together with its subsidiaries, produces specialty ingredients with applications in food, health, nutrition, and industrial markets. It operates through three segments: Food, Health and Nutrition; Industrial Specialties; and Other. The company's specialty ingredients include specialty phosphate salts and specialty phosphoric acids, as well as other mineral, enzyme, and botanical based specialty ingredients that are used as flavor enhancers in beverages; electrolytes in sports drinks; texture modifiers in cheeses; leavening agents in baked goods; calcium and phosphorus fortification in food and beverages; moisture and color retention in seafood, poultry, and meat; excipients in vitamins, minerals, nutritional supplements, and pharmaceuticals; and abrasives in toothpaste.

Featured Article: Should you buy a closed-end mutual fund?

Get a free copy of the Zacks research report on Innophos (IPHS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Innophos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innophos and related companies with MarketBeat.com's FREE daily email newsletter.